Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: A phase II study

British Journal of Cancer

Volumn 90, Issue 8, 2004, Pages 1502-1507

  Feliu, J ^a   Salud, A ^b   Escudero, P ^c   Lopez Gomez L ^d   Pericay, C ^e   Castanon C ^f   Lopez De Tejada M R ^g   Rodriguez Garcia J M ^h   Martinez M P ⁱ   Sanz Martin M ^j   Sanchez J J ^k   Gonzalez Baron M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Hosp Amau Vilanova de Lérida   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e HS Pau de Barcelona   (Spain)

^f Hospital General de Leon   (Spain)

^g HOSPITAL PUNTA DE EUROPA   (Spain)

^h HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

ⁱ HOSPITAL DE BASURTO   (Spain)

^j Hospital Alarcos   (Spain)

^k UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

more..

Author keywords

Chemotherapy; Colorectal cancer; CPT 11; Irinotecan; Raltitrexed

Indexed keywords

AMINOTRANSFERASE; ANTIEMETIC AGENT; IRINOTECAN; LOPERAMIDE; RALTITREXED; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; AUTONOMIC DYSFUNCTION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHOLINERGIC SYNDROME; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERANCE; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; COLORECTAL TUMOR; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; QUINAZOLINES; SURVIVAL ANALYSIS; THIOPHENES; TREATMENT OUTCOME;

EID: 2442456768     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601713     Document Type: Article

References (31)

1. Aparicio J, Vicent JM, Maestu I, Garcera S, Busquier I, Bosch C, Llorca C, Díaz R, Fernández-Martos C, Galán A (2003) Multicenter phase II trial evaluating a three-weekly scheduled irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory, advanced colorectal cancer. Ann Oncol 14: 1121-1125
2. Aschele C, Baldo C, Sobrero AF, Debernardis D, Bornmann WG, Bertino JR (1998) Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res 4: 1323-1330
3. Carnaghi C, Rimassa L, Garassino I, Zucali PA, Masci G, Fallini M, Morenghi E, Santoro A (2002) Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. Ann Oncol 13: 1424-1429
4. Cocconi G, Cunningham D, Van Custem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM (1998) Open, randomized multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 16: 2943-2952
5. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
6. Colucci G, Giuliani F, Giotta F, Galetta D, Brandi M, Naglieri E, Vinciarelli G, Maiello E (2001) Irinotecan (CPT-11) and Raltitrexed (Tomudex) combination therapy in the treatment of advanced colorectal cancer (ACC): a phase I/II study. Proc Am Soc Clin Oncol 20: 146a (abstract 580)
7. Cunningham D, Zalcberg J, Smith IE (1994) 'Tomudex': a novel thymidilate synthase (TS) inhibitor with clinical antitumour activity in a range of solid tumours. Ann Oncol 5(Suppl 8): 179 (abstract 904)
8. Cunningham D, Zalcberg JR, Rath U, Olver I, Van Custem E, Svensson C, Seitz JF, Haper P, Kerr D, Perez-Manga G (1995) 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 31: 1945-1954
9. Cunningham D, Zalcberg J, Maroun J, James R, Clarke S, Maughan TS, Vincent M, Schultz J, Gonzalez Baron M, Facchini T (2002) Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials. Eur J Cancer 38: 478-486
10. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047
11. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143-151
12. Ford HER, Cunningham D, Ross PJ, Rao S, Aherne GW, Benepal TS, Price T, Massey A, Vernillet L, Gruia G (2000) Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. Br J Cancer 83: 146-152
13. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitovich F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levy F (2000) Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136-147
14. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
15. Groener MG, van Ineveld BM, Byttebier G, van Hot BA, Rutten F (1999) An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Anticancer Drugs 10: 283-288
16. Hale JP, Cohn DR, Maughan TS, Stephns RJ (2002) Cost and consequences of different chemotherapy regimen in metastatic colorectal cancer. Br J Cancer 96: 1684-1690
17. Jackman AL, Kimbell R, Ford HE (1999) Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations. Eur J Cancer 35(Suppl 1): S3-S8
18. Jansman FG, Sleijfer DT, Coenen JL, De Graaf JC, Brouwers JR (2000) Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf 23: 255-278
19. Judson I, Maughan TS, Beale P, Primrose J, Hoskin P, Hawell J, Berry C, Walker M, Sutcliffe F (1998) Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex, ZD1694). Br J Cancer 78: 118-1193
20. Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schoffski F, Micheel S, Hecker H (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13: 308-317
21. Ledermann JA, Leonard P, Seymour M (2001) Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345: 145-146
22. Lewis NL, Scher R, Gallo JM, Engstrom PF, Szarka CE, Litwin S, Adams AL, Kilpatrick D, Brady D, Weiner LM, Meropol NJ (2002) Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed. Cancer Chemother Pharmacol 50: 257-265
23. Maughan TS, James RD, Kerr DJ, Lederrmann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ (2002) British MRC Colorectal Cancer Working Party. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer a multicentre randomized trial. Lancet 359: 1555-1563
24. Pazdur R, Vicent M (1997) Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5FU+LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 16: 228 (abstract 801)
25. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801-3807
26. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914
27. Stevenson JP, Redlinger M, Kluijtmans LAJ, Weijing S, Algazy K, Giantonio B, Haller DG, Hardy C, Whitehead AS, ÓDwyer PJ (2001) Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol 19: 4081-4087
28. Thomas RJ (2000) Optimising the side effects of raltitrexed with appropiate supportive drugs. A prospective community hospital study. Proc Am Soc Clin Oncol 19: 308 (abstract 1217)
29. Van Custem E, Cunningham D, Maroun J, Cervantes A, Glimelius B (2002) Raltitrexed: current clinical status and future directions. Ann Oncol 13: 513-522
30. World Health Organization (WHO) (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication no. 48, Geneva, Switzerland
31. Young A, Topham C, Moore J, Turner J, Wardle J, Downes M, Evans V, Kay S (1999) A patient preference study comparing raltitrexed (Tomudex) and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes. Eur J Cancer Care 8: 154-161